We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Structural Blueprints of Lnt Enzyme Revealed

News   Aug 24, 2017 | Original Story from Trinity College Dublin

 
Structural Blueprints of Lnt Enzyme Revealed

(a) View from the membrane plane. The protein has two domains, a membrane domain and a periplasmic nitrilase-like domain. The structure is shown in cartoon representation and rainbow colour coded from N (blue) to C terminus (red). The catalytic cysteine Cys387 side chain is shown in sphere representation (carbon, magenta; sulfur, yellow). The magenta arrow indicates the proposed substrate entry portal and identifies what is referred to as the front of the enzyme. Approximate location of the membrane boundaries are shown as horizontal lines. Cys387 sits ∼13 Å above the bulk membrane surface. (b) Schematic representation of the secondary structure elements in the LntEco structure. Colour coding follows that used in a. Credit: Professor Martin Caffrey, Trinity College Dubin.

 
 
 

RELATED ARTICLES

Clinical Trial Assessing Treatments for Preventing People at High Risk From Developing Multidrug-resistant TB Launches

News

A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.

READ MORE

New Hope for Aggressive Breast Cancer: Diabetes Drug Creates Treatment “Sweet Spot”

News

New research funded by Breast Cancer Now has shown that a drug commonly used to treat Type 2 diabetes could make breast cancer cells susceptible to new treatments.

READ MORE

Widely Available Antibiotics Could Be Used to Treat “Superbug” MRSA

News

Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE